Dear Sir, In a recent paper [1] Dr. Tesfaye and co-workers describe morphological and functional alterations of nutritional blood vessels of sural nerve in patients with diabetic neuropathy, detected by novel techniques. Their findings strongly support the hypothesis that diabetic neuropathy [2] [3] [4] is based on diabetic angiopathy within the "vasa nervorum" with subsequent tissue hypoxia. Even if diabetic neuropathy is undoubtedly accompanied by or based on morphological vascular abnormalities, some points concerning the data on nerve fluorescein angiography should be furt]her discussed.
On one hand, the authors show significantly reduced fluorescence intensity in patients with diabetic neuropathy compared to healthy control subjects or non-neuropathic diabetic patients. On the other hand, they observe a non-significant increase in fluorescence intensity in non-neuropathic patients compared to control subjects. Mean differences in fluorescence intensity, calculated from Table 3 , between control subjects and neuropathic patients (1.10 after 372 s and 1.26 after 576 s) and between control subjects and non-neuropathic patients (1.15 after 372 s and 1.18 after 576 s) are very similar. Therefore, this non-significance seems to be based on a very small number of observations and a heterogeneity of the nonneuropathic group rather than on a lack of real difference. This directly leads to the main problem of the results: the authors discuss increased fluorescence as comparable to increased blood flow seen in early uncomplicated diabetes in retina [5] , kidney [6] or skin [7] . But both increased blood flow and vascular leakage have been shown by Tilton et al. and Corbett et al. [8, 9] and our group [10] to be a result of hyperglycaemia (i. e. glucotoxicity) itself and to be related to an increased endothelial formation of nitric oxide. Such functional alterations are found in morphologically intact vessels before the occurrence of morphological changes and can be termed "endothelial dysfunction" [11] . Therefore, in our opinion, two points may be criticized. First, in the non-neuropathic group only one patient Corresponding author: The Diabetic Angiopathy Research Group, Dr. T. C.Wascher, University of Graz, Department of Internal Medicine, Auenbruggerplatz 15, A-8036 Graz, Austria was free from retinopathy. On the other hand it has been clearly demonstrated that increased blood flow decreases with the onset of vascular complications such as retinopathy [7] and becomes pseudo-normal before being impaired. Second, the same patient had the highest fluorescence intensity by far, suggesting a high blood flow at a lower rate of vascular leakage than in the other patients of this group since HbA 1 was the lowest of all. Thus, excluding patients with overt diabetic angiopathy (i. e. retinopathy) would probably have resulted in a more homogeneous group with even higher fluorescence intensity (flow). Furthermore, glycaemic control should be matched whenever comparing parameters of blood flow to exclude differences in nitric oxide formation or vascular leakage.
Despite these precautions the results perfectly match the hypothesis of early increases of blood flow in tissues preferentially affected by diabetic complications. As a result of this increased flow, resistance-work might be shifted downstream towards smaller vessels thus facilitating the occurrence of angiopathy by local, microvascular hypertension.
In conclusion, the techniques described in this paper provide a new, powerful tool to study the effects of early intervention with drugs such as aminoguanidine [12] Response from the authors Dear Sir, We are grateful to Drs. Wascher and Toplak for their comments about our work involving photography of sural nerve vessels and fluorescein angiography. We accept their comment that there is a need to make similar observations in nonneuropathic diabetic patients who do not obviously have microvascular complications, but as the procedure involved was significantly invasive, although with no long-term complications, the number of non-neuropathic subjects volunteering to undergo the procedure during the study period was rather limited. This was in contrast to the number of neuropathic patients who were often very willing to volunteer for the procedure. We are now in the process of developing techniques for measuring nerve blood flow including fluorescein angiography through a Corresponding author." Dr. S.Tesfaye, The Diabetes Center, Walton Hospital, Rice Lane, Liverpool L9 IAE, UK much reduced incision as the technique of light-guide spectrophotometry and laser Doppler has been developed and miniaturised. The other point raised by Drs. Wascher and Toplak was the need to match glycaemic control when comparing indices of blood flow. There was no significant difference in either mean HbA 1 or mean ambient blood glucose between both the diabetic groups, nor was there any correlation between the intensity of fluorescence and HbA 1, although admittedly the numbers could have been too small for a decent correlation.
We accept there is a great need to investigate the effect of various therapeutic agents on nerve blood flow (gamma linolenic acid, angiotensin converting enzyme inhibitors) and we hope that our miniaturised technique will allow such studies.
Yours sincerely, S. Tesfaye, J. D. Ward
